Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer

NCT03168074 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT03168074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03168074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Unknown status
Start date
March 28, 2017
Completion date
March 28, 2021
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer